Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alvotech ( (ALVO) ) just unveiled an update.
Alvotech reported financial results for the first half of 2025, showing a significant increase in product revenue to $204.7 million compared to $65.9 million in the same period in 2024, driven by the expansion of AVT02 and the launch of AVT04 in multiple countries. Despite a decrease in license and other revenue, the company achieved a net profit of $141.7 million, a substantial turnaround from a net loss in the previous year. Alvotech also announced several strategic initiatives, including a collaboration with Dr. Reddy’s Laboratories for a Keytruda biosimilar and an expanded partnership with Advanz Pharma for additional biosimilar candidates, positioning the company for further growth in the biosimilars market.
The most recent analyst rating on (ALVO) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall score reflects its strong earnings call performance and promising revenue growth. However, significant financial risks due to high leverage and negative equity, combined with neutral technical indicators, moderate the score. The valuation is reasonable, but the absence of a dividend yield may deter some investors.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a biotech company specializing in the development and manufacture of biosimilar medicines aimed at improving global patient access to affordable treatments for various diseases. Founded in 2013, the company leverages a purpose-built R&D and manufacturing platform, commercial partnerships, and a diverse pipeline to address major global health challenges, including autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.
Average Trading Volume: 260,784
Technical Sentiment Signal: Sell
Current Market Cap: $2.61B
See more insights into ALVO stock on TipRanks’ Stock Analysis page.